## Andrea Schmitt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4993724/publications.pdf Version: 2024-02-01

		36203	56606
222	8,659	51	83
papers	citations	h-index	g-index
235	235	235	11371
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH). European Psychiatry, 2018, 54, 124-144.	0.1	377
2	microRNA-34c is a novel target to treat dementias. EMBO Journal, 2011, 30, 4299-4308.	3.5	302
3	The impact of environmental factors in severe psychiatric disorders. Frontiers in Neuroscience, 2014, 8, 19.	1.4	242
4	Differential Expression of Exosomal microRNAs in Prefrontal Cortices of Schizophrenia and Bipolar Disorder Patients. PLoS ONE, 2013, 8, e48814.	1.1	205
5	Schizophrenia as a disorder of disconnectivity. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 150-154.	1.8	197
6	Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 151-163.	1.8	180
7	Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 367-377.	1.8	177
8	Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. Journal of Psychiatric Research, 2009, 43, 978-986.	1.5	165
9	Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: Further evidence for disease course-related immune alterations?. Brain, Behavior, and Immunity, 2012, 26, 1273-1279.	2.0	165
10	Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiology of Aging, 2004, 25, 1299-1303.	1.5	162
11	Increased platelet phospholipase A2 activity in schizophrenia. Schizophrenia Research, 1995, 16, 1-6.	1.1	158
12	Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. Journal of Psychiatric Research, 2010, 44, 1176-1189.	1.5	158
13	Neural correlates of working memory dysfunction in first-episode schizophrenia patients: An fMRI multi-center study. Schizophrenia Research, 2007, 89, 198-210.	1.1	148
14	Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathologica, 2009, 117, 395-407.	3.9	146
15	Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. Journal of Neural Transmission, 2009, 116, 275-289.	1.4	137
16	Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry, 2009, 9, 17.	1.1	133
17	Effects of aerobic exercise on cognitive performance and individual psychopathology in depressive and schizophrenia patients. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 589-604.	1.8	133
18	Effects of Formalin Fixation, Paraffin Embedding, and Time of Storage on DNA Preservation in Brain Tissue: A BrainNet Europe Study. Brain Pathology, 2007, 17, 297-303.	2.1	127

#	Article	IF	CITATIONS
19	Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. Journal of Neural Transmission, 2015, 122, 1055-1068.	1.4	126
20	Altered thalamic membrane phospholipids in schizophrenia: a postmortem study. Biological Psychiatry, 2004, 56, 41-45.	0.7	111
21	Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathologica, 2012, 124, 893-903.	3.9	110
22	Differential gene expression in peripheral blood of patients suffering from post-traumatic stress disorder. Molecular Psychiatry, 2007, 12, 116-118.	4.1	109
23	Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 497-507.	3.9	101
24	Childhood Trauma in Schizophrenia: Current Findings and Research Perspectives. Frontiers in Neuroscience, 2019, 13, 274.	1.4	99
25	pH measurement as quality control on human <i>post mortem</i> brain tissue: a study of the BrainNet Europe consortium. Neuropathology and Applied Neurobiology, 2009, 35, 329-337.	1.8	93
26	The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics, 2011, 66, 71-77.	0.6	91
27	The effects of physical exercise in schizophrenia and affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 451-467.	1.8	90
28	Hippocampal volume in chronic posttraumatic stress disorder (PTSD): MRI study using two different evaluation methods. Journal of Affective Disorders, 2006, 94, 121-126.	2.0	84
29	Kraepelin revisited: schizophrenia from degeneration to failed regeneration. Molecular Psychiatry, 2015, 20, 671-676.	4.1	83
30	Effects of Endurance Training Combined With Cognitive Remediation on Everyday Functioning, Symptoms, and Cognition in Multiepisode Schizophrenia Patients. Schizophrenia Bulletin, 2015, 41, 847-858.	2.3	83
31	Proteome analysis of schizophrenia brain tissue. World Journal of Biological Psychiatry, 2010, 11, 110-120.	1.3	82
32	Relapse Prevention in First-Episode Schizophrenia—Maintenance vs Intermittent Drug Treatment With Prodrome-Based Early Intervention. Journal of Clinical Psychiatry, 2011, 72, 205-218.	1.1	79
33	Maintenance Treatment With Risperidone or Low-Dose Haloperidol in First-Episode Schizophrenia. Journal of Clinical Psychiatry, 2007, 68, 1763-1774.	1.1	76
34	HDAC1 links early life stress to schizophrenia-like phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E4686-E4694.	3.3	75
35	Differential Effects of Long-Term Treatment with Clozapine or Haloperidol on GABA Transporter Expression. Pharmacopsychiatry, 2004, 37, 171-174.	1.7	74
36	Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia. Journal of Psychiatric Research, 2010, 44, 989-991.	1.5	72

#	Article	IF	CITATIONS
37	Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 601-612.	1.8	70
38	Increased serum S100B in elderly, chronic schizophrenic patients: Negative correlation with deficit symptoms. Schizophrenia Research, 2005, 80, 305-313.	1.1	68
39	Decreased Oligodendrocyte and Neuron Number in Anterior Hippocampal Areas and the Entire Hippocampus in Schizophrenia: A Stereological Postmortem Study. Schizophrenia Bulletin, 2016, 42, S4-S12.	2.3	68
40	Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain. Neuroscience Letters, 2003, 347, 81-84.	1.0	65
41	Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry, 2009, 10, 127-155.	1.3	64
42	Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. NPJ Schizophrenia, 2015, 1, 15034.	2.0	64
43	Effects of endurance training on brain structures in chronic schizophrenia patients and healthy controls. Schizophrenia Research, 2016, 173, 182-191.	1.1	64
44	Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World Journal of Biological Psychiatry, 2011, 12, 201-215.	1.3	60
45	Increased serum interleukin-I? and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. Neuropsychiatric Disease and Treatment, 2005, 1, 171-177.	1.0	59
46	The effect of aerobic exercise on cortical architecture in patients with chronic schizophrenia: a randomized controlled MRI study. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 469-473.	1.8	58
47	Reduced oxytocin receptor gene expression and binding sites in different brain regions in schizophrenia: A post-mortem study. Schizophrenia Research, 2016, 177, 59-66.	1.1	58
48	Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophrenia Research, 2004, 66, 151-157.	1.1	57
49	Effects of Aerobic Exercise on Metabolic Syndrome, Cardiorespiratory Fitness, and Symptoms in Schizophrenia Include Decreased Mortality. Frontiers in Psychiatry, 2018, 9, 690.	1.3	57
50	Polygenic risk has an impact on the structural plasticity of hippocampal subfields during aerobic exercise combined with cognitive remediation in multi-episode schizophrenia. Translational Psychiatry, 2017, 7, e1159-e1159.	2.4	56
51	Disturbance in the neural circuitry underlying positive emotional processing in post–traumatic stress disorder (PTSD). European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 112-114.	1.8	55
52	Pedophilia: neuropsychological evidence encouraging a brain network perspective. Medical Hypotheses, 2004, 63, 528-531.	0.8	53
53	Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment. Journal of Neural Transmission, 2004, 111, 91-100.	1.4	52
54	Effects of Long-Term Antipsychotic Treatment on NMDA Receptor Binding and Gene Expression of Subunits. Neurochemical Research, 2003, 28, 235-241.	1.6	51

#	Article	IF	CITATIONS
55	CACNA1C genotype explains interindividual differences in amygdala volume among patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 93-102.	1.8	50
56	How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. Journal of Neural Transmission, 2007, 114, 527-537.	1.4	49
57	Oligodendrocytes as A New Therapeutic Target in Schizophrenia: From Histopathological Findings to Neuron-Oligodendrocyte Interaction. Cells, 2019, 8, 1496.	1.8	49
58	Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World Journal of Biological Psychiatry, 2010, 11, 719-728.	1.3	47
59	Predictors of response and remission in the acute treatment of first-episode schizophrenia patients — Is it all about early response?. European Neuropsychopharmacology, 2011, 21, 370-378.	0.3	46
60	Formin 2 links neuropsychiatric phenotypes at young age to an increased risk for dementia. EMBO Journal, 2017, 36, 2815-2828.	3.5	45
61	Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins. Neurotoxicity Research, 2011, 19, 603-627.	1.3	44
62	Synaptosomal Proteome of the Orbitofrontal Cortex from Schizophrenia Patients Using Quantitative Label-Free and iTRAQ-Based Shotgun Proteomics. Journal of Proteome Research, 2017, 16, 4481-4494.	1.8	44
63	Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 101-111.	1.8	41
64	Association of the brain-derived neurotrophic factor val66met polymorphism with magnetic resonance spectroscopic markers in the human hippocampus: in vivo evidence for effects on the glutamate system. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 23-31.	1.8	41
65	Aerobic exercise and its effects on cognition in schizophrenia. Current Opinion in Psychiatry, 2017, 30, 171-175.	3.1	41
66	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World Journal of Biological Psychiatry, 2010, 11, 243-250.	1.3	40
67	Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 3-13.	1.8	40
68	vaccine development: Facing the challenge. International Journal of Medical Microbiology, 2005, 295, 343-353.	1.5	38
69	D2 Antidopaminergic Modulation of Frontal Lobe Function in Healthy Human Subjects. Biological Psychiatry, 2006, 60, 1196-1205.	0.7	37
70	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology. World Journal of Biological Psychiatry, 2015, 16, 280-290.	1.3	37
71	Oligodendrocyte and Interneuron Density in Hippocampal Subfields in Schizophrenia and Association of Oligodendrocyte Number with Cognitive Deficits. Frontiers in Cellular Neuroscience, 2016, 10, 78.	1.8	37
72	Reduced density of ADAM 12-immunoreactive oligodendrocytes in the anterior cingulate white matter of patients with schizophrenia. World Journal of Biological Psychiatry, 2010, 11, 556-566.	1.3	36

#	Article	IF	CITATIONS
73	Decreased Reelin Expression in the Left Prefrontal Cortex (BA9) in Chronic Schizophrenia Patients. Neuropsychobiology, 2012, 66, 57-62.	0.9	36
74	MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia. Frontiers in Cellular Neuroscience, 2015, 09, 180.	1.8	35
75	Neurobiological effects of aerobic exercise, with a focus on patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 499-515.	1.8	35
76	Internal capsule size associated with outcome in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 278-283.	1.8	34
77	Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia. Schizophrenia Research, 2016, 170, 168-176.	1.1	34
78	Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. Schizophrenia Research, 2014, 152, 478-486.	1.1	33
79	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World Journal of Biological Psychiatry, 2017, 18, 330-356.	1.3	33
80	The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains. Molecular Neuropsychiatry, 2017, 3, 37-52.	3.0	32
81	Increased d-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study. Journal of Neural Transmission, 2009, 116, 1657-1665.	1.4	31
82	Structural synaptic elements are differentially regulated in superior temporal cortex of schizophrenia patients. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 565-577.	1.8	31
83	Ten years of proteomics in multiple sclerosis. Proteomics, 2014, 14, 467-480.	1.3	31
84	Studying and modulating schizophrenia-associated dysfunctions of oligodendrocytes with patient-specific cell systems. NPJ Schizophrenia, 2018, 4, 23.	2.0	31
85	Forty years of structural brain imaging in mental disorders: is it clinically useful or not?. Dialogues in Clinical Neuroscience, 2018, 20, 179-186.	1.8	31
86	Association between myelin basic protein expression and left entorhinal cortex pre-alpha cell layer disorganization in schizophrenia. Brain Research, 2009, 1301, 126-134.	1.1	30
87	Abnormal bihemispheric responses in schizophrenia patients following cathodal transcranial direct stimulation. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 415-423.	1.8	30
88	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 406-428.	1.3	30
89	Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 72-79.	1.8	29
90	Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. Neurochemistry International, 2009, 55, 619-628.	1.9	29

#	Article	IF	CITATIONS
91	Akathisia and Suicidal Ideation in First-Episode Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 694-698.	0.7	29
92	A new role for oligodendrocytes and myelination in schizophrenia and affective disorders?. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 371-372.	1.8	29
93	Huntington's Disease: Phenomenological Diversity of a Neuropsychiatric Condition That Challenges Traditional Concepts in Neurology and Psychiatry. American Journal of Psychiatry, 2004, 161, 28-34.	4.0	28
94	Protective Drugs in Acute Large-Dose Exposure to Organophosphates: A Comparison of Metoclopramide and Tiapride with Pralidoxime in Rats. Anesthesia and Analgesia, 2005, 100, 382-386.	1.1	28
95	Behavioural Alterations in Rats Following Neonatal Hypoxia and Effects of Clozapine: Implications for Schizophrenia. Pharmacopsychiatry, 2008, 41, 138-145.	1.7	28
96	Effect of in vitro hemodilution with hydroxyethyl starch and dextran on the activity of plasma clotting factors. Critical Care Medicine, 2003, 31, 250-254.	0.4	27
97	GABAergic system impairment in the hippocampus and superior temporal gyrus of patients with paranoid schizophrenia: A post-mortem study. Schizophrenia Research, 2016, 177, 10-17.	1.1	27
98	Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial. European Psychiatry, 2009, 24, 33-40.	0.1	26
99	New lexicon and criteria for the diagnosis of Alzheimer's disease. Lancet Neurology, The, 2011, 10, 298-299.	4.9	26
100	Increased Density of Prohibitin-Immunoreactive Oligodendrocytes in the Dorsolateral Prefrontal White Matter of Subjects with Schizophrenia Suggests Extraneuronal Roles for the Protein in the Disease. NeuroMolecular Medicine, 2012, 14, 270-280.	1.8	25
101	BDNF-Val66Met-Polymorphism Impact on Cortical Plasticity in Schizophrenia Patients: A Proof-of-Concept Study. International Journal of Neuropsychopharmacology, 2015, 18, .	1.0	25
102	Stereological investigation of the posterior hippocampus in affective disorders. Journal of Neural Transmission, 2015, 122, 1019-1033.	1.4	25
103	Differential expression of HINT1 in schizophrenia brain tissue. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 167-172.	1.8	24
104	Effects of cannabis and familial loading on subcortical brain volumes in first-episode schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 155-168.	1.8	24
105	The human oligodendrocyte proteome. Proteomics, 2013, 13, 3548-3553.	1.3	24
106	Dysregulation of a specific immune-related network of genes biologically defines a subset of schizophrenia. Translational Psychiatry, 2019, 9, 156.	2.4	24
107	Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: Comparing treatment with risperidone and haloperidol. World Journal of Biological Psychiatry, 2012, 13, 30-38.	1.3	23
108	Ethanol Induces Expression of the Glutamate Transporters EAAT1 and EAAT2 in Organotypic Cortical Slice Cultures. Alcoholism: Clinical and Experimental Research, 2004, 28, 1752-1757.	1.4	22

#	Article	IF	CITATIONS
109	Altered NMDA receptor expression and behavior following postnatal hypoxia: potential relevance to schizophrenia. Journal of Neural Transmission, 2007, 114, 239-248.	1.4	22
110	Endurance training in patients with schizophrenia and healthy controls: differences and similarities. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 461-473.	1.8	22
111	Differential proteome and phosphoproteome may impact cell signaling in the corpus callosum of schizophrenia patients. Schizophrenia Research, 2016, 177, 70-77.	1.1	22
112	Peptidomic analysis of the anterior temporal lobe and corpus callosum from schizophrenia patients. Journal of Proteomics, 2017, 151, 97-105.	1.2	22
113	Shotgun mass spectrometry analysis of the human thalamus proteome. Journal of Separation Science, 2009, 32, 1231-1236.	1.3	21
114	A systematic review of trials investigating strength training in schizophrenia spectrum disorders. Schizophrenia Research, 2018, 192, 64-68.	1.1	21
115	The need to develop personalized interventions to improve cognition in schizophrenia. World Psychiatry, 2019, 18, 170-170.	4.8	21
116	Quantitative Subcellular Proteomics of the Orbitofrontal Cortex of Schizophrenia Patients. Journal of Proteome Research, 2019, 18, 4240-4253.	1.8	21
117	Effect of aerobic exercise combined with cognitive remediation on cortical thickness and prediction of social adaptation in patients with schizophrenia. Schizophrenia Research, 2020, 216, 397-407.	1.1	21
118	Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 35-39.	1.8	20
119	Is Brain Banking of Psychiatric Cases Valuable for Neurobiological Research?. Clinics, 2008, 63, 255-266.	0.6	20
120	Effects of chronic oral treatment with aripiprazole on the expression of NMDA receptor subunits and binding sites in rat brain. Psychopharmacology, 2011, 217, 127-142.	1.5	20
121	Antipsychotic treatment modulates glutamate transport and NMDA receptor expression. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 67-82.	1.8	20
122	Increased cell proliferation in the rat anterior cingulate cortex following neonatal hypoxia: relevance to schizophrenia. Journal of Neural Transmission, 2013, 120, 187-195.	1.4	19
123	Stigma experiences and perceived stigma in patients with first-episode schizophrenia in the course of 1Âyear after their first in-patient treatment. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 459-468.	1.8	19
124	S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 311-316.	1.8	18
125	The effect of physical activity in an alpine environment on quality of life is mediated by resilience in patients with psychosomatic disorders and healthy controls. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 543-553.	1.8	18
126	Depression in Somatic Disorders: Is There a Beneficial Effect of Exercise?. Frontiers in Psychiatry, 2019, 10, 141.	1.3	18

#	Article	IF	CITATIONS
127	The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. Clinics, 2010, 65, 885-894.	0.6	17
128	Deciphering the Human Brain Proteome: Characterization of the Anterior Temporal Lobe and Corpus Callosum As Part of the Chromosome 15-centric Human Proteome Project. Journal of Proteome Research, 2014, 13, 147-157.	1.8	16
129	Reduction of gyrification index in the cerebellar vermis in schizophrenia: A post-mortem study. World Journal of Biological Psychiatry, 2011, 12, 99-103.	1.3	15
130	Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment. World Journal of Biological Psychiatry, 2013, 14, 490-499.	1.3	15
131	Aerobic exercise in severe mental illness: requirements from the perspective of sports medicine. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 643-677.	1.8	15
132	Aripiprazole differentially regulates the expression of Gad67 and Î <sup>3</sup> -aminobutyric acid transporters in rat brain. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 285-297.	1.8	14
133	Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients. Translational Psychiatry, 2019, 9, 284.	2.4	14
134	Association Between Physical Activity and Schizophrenia. JAMA Psychiatry, 2021, 78, 441.	6.0	14
135	Proteome analysis of human dorsolateral prefrontal cortex using shotgun mass spectrometry. Journal of Separation Science, 2008, 31, 3122-3126.	1.3	13
136	Tryptophan is a marker of human postmortem brain tissue quality. Journal of Neurochemistry, 2009, 110, 1400-1408.	2.1	13
137	Sex-dependent behavioral effects and morphological changes in the hippocampus after prenatal invasive interventions in rats: implications for animal models of schizophrenia. Clinics, 2010, 65, 209-219.	0.6	12
138	Methyl- and acetyltransferases are stable epigenetic markers postmortem. Cell and Tissue Banking, 2011, 12, 289-297.	0.5	12
139	Proteomic Similarities Between Heterozygous Reeler Mice and Schizophrenia. Biological Psychiatry, 2013, 74, e5-e10.	0.7	11
140	Pioneering ambient mass spectrometry imaging in psychiatry: Potential for new insights into schizophrenia. Schizophrenia Research, 2016, 177, 67-69.	1.1	11
141	Aerobic endurance training to improve cognition and enhance recovery in schizophrenia: design and methodology of a multicenter randomized controlled trial. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 315-324.	1.8	11
142	Sexâ€dependent alterations of dopamine receptor and glucose transporter density in rat hypothalamus under longâ€ŧerm clozapine and haloperidol medication. Brain and Behavior, 2020, 10, e01694.	1.0	10
143	Improvement in daily functioning after aerobic exercise training in schizophrenia is sustained after exercise cessation. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1201-1203.	1.8	10
144	Exercise as a model to identify microRNAs linked to human cognition: a role for microRNA-409 and microRNA-501. Translational Psychiatry, 2021, 11, 514.	2.4	10

#	Article	IF	CITATIONS
145	Psychiatrists' self-stigma, the DGPPN guideline for psychosocial interventions, and contemporary treatment strategies. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 171-172.	1.8	9
146	Effects of haloperidol and clozapine on synapse-related gene expression in specific brain regions of male rats. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 555-563.	1.8	9
147	Association between altered hippocampal oligodendrocyte number and neuronal circuit structures in schizophrenia: a postmortem analysis. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 413-424.	1.8	9
148	An overview of the human brain myelin proteome and differences associated with schizophrenia. World Journal of Biological Psychiatry, 2021, 22, 271-287.	1.3	8
149	Nonpharmacological treatment of dyscognition in schizophrenia: effects †of aerobic exercise. Dialogues in Clinical Neuroscience, 2019, 21, 261-269.	1.8	8
150	Medication Adherence in a Cross-Diagnostic Sample of Patients From the Affective-to-Psychotic Spectrum: Results From the PsyCourse Study. Frontiers in Psychiatry, 2021, 12, 713060.	1.3	8
151	Pattern and volume of the anterior cingulate cortex in chronic posttraumatic stress disorder (PTSD). European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 585-592.	1.8	7
152	Neuroscience-based nomenclature (jNbN) to replace traditional terminology of psychotropic medications. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 385-386.	1.8	7
153	Aerobic exercise in mental disorders: from basic mechanisms to treatment recommendations. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 483-484.	1.8	7
154	The Influence of Continuous Exercising on Chronotropic Incompetence in Multi-Episode Schizophrenia. Frontiers in Psychiatry, 2019, 10, 90.	1.3	7
155	T1-MPRAGE and T2-FLAIR segmentation of cortical and subcortical brain regions—an MRI evaluation study. Neuroradiology, 2019, 61, 129-136.	1.1	7
156	Disfunção pré-frontoparietal durante o processamento de informação visuoauditiva em pacientes idosos com esquizofrenia crônica e efeitos da medicação. Revista De Psiquiatria Clinica, 2009, 36, 89-96.	0.6	6
157	Thalamic nuclear abnormalities as a contributory factor in sudden cardiac deaths among patients with schizophrenia. Clinics, 2010, 65, 539-546.	0.6	6
158	The impact of endurance training and table soccer on brain metabolites in schizophrenia. Brain Imaging and Behavior, 2020, 14, 515-526.	1.1	6
159	The LARK/RBM4a protein is highly expressed in cerebellum as compared to cerebrum. Neuroscience Letters, 2008, 444, 11-15.	1.0	5
160	Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 1579-1586.	1.8	5
161	Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. World Journal of Biological Psychiatry, 0, , 1-8.	1.3	5
162	Expression of Lineage Transcription Factors Identifies Differences in Transition States of Induced Human Oligodendrocyte Differentiation. Cells, 2022, 11, 241.	1.8	5

#	Article	IF	CITATIONS
163	Aerobic exercise in major psychiatric disorders: promises and challenges. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 93-94.	1.8	4
164	Differential gene regulation in the anterior cingulate cortex and superior temporal cortex in schizophrenia: A molecular network approach. Schizophrenia Research, 2021, 232, 1-10.	1.1	4
165	Sex-dependent effects of long-term clozapine or haloperidol medication on red blood cells and liver iron metabolism in Sprague Dawley rats as a model of metabolic syndrome. BMC Pharmacology & Toxicology, 2022, 23, 8.	1.0	4
166	Association between aerobic fitness and the functional connectome in patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 1253-1272.	1.8	4
167	Therapeutic targets in major psychiatric disorders revisited. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 619-620.	1.8	3
168	The neuropathology of schizophrenia: new insights from postmortem studies. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 269-270.	1.8	3
169	Negative symptoms and therapy strategies in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 541-542.	1.8	3
170	Effects of Three Months of Aerobic Endurance Training on Motor Cortical Excitability in Schizophrenia Patients and Healthy Subjects. Neuropsychobiology, 2020, 79, 100-107.	0.9	3
171	Viewing an alpine environment positively affects emotional analytics in patients with somatoform, depressive and anxiety disorders as well as in healthy controls. BMC Psychiatry, 2020, 20, 385.	1.1	3
172	The Neuropathology of Schizophrenia: Central Role for the Hippocampus?. , 2010, , 149-165.		3
173	Estudos transcriptômicos no contexto da conectividade perturbada em esquizofrenia. Revista De Psiquiatria Clinica, 2013, 40, 10-15.	0.6	3
174	Differential diagnosis of major depression and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 83-84.	1.8	2
175	The new risk variant CACNA1C and brain circuits in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 91-92.	1.8	2
176	Comorbidity, stigma and emotional perception in psychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 1-2.	1.8	2
177	Historical aspects of Mozart's mental health and diagnostic insights of ADHD and personality disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 363-365.	1.8	2
178	Suicide ideation, stability of symptoms and effects of aerobic exercise in major depression. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 555-556.	1.8	2
179	Erythropoietin as an Innovative Add-on Therapy for Depression. Biological Psychiatry, 2015, 78, 222-223.	0.7	2
180	Schizophrenia spectrum and related neuropathology. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 85-86.	1.8	2

#	Article	IF	CITATIONS
181	Classification and neurobiological concepts of mania, bipolar disorder and major depression. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 271-272.	1.8	2
182	News from the graveyard: Neuropathological research on schizophrenia is alive and productive. Schizophrenia Research, 2016, 177, 1-2.	1.1	2
183	Perspectives of neurobiological research in schizophrenia. Neurology Psychiatry and Brain Research, 2016, 22, 63-68.	2.0	2
184	Morphological and functional alterations in patients with schizophrenia spectrum disorders. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 1-2.	1.8	2
185	Impact of the metabolic syndrome on severe mental disorders. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 499-500.	1.8	2
186	Effect of aerobic exercise on cortical thickness in patients with schizophrenia—A dataset. Data in Brief, 2020, 30, 105517.	0.5	2
187	Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health. Frontiers in Psychiatry, 2022, 13, 815718.	1.3	2
188	Schizophrenia: from risk genes to outcome and comorbidity. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 547-548.	1.8	1
189	Impact of lifestyle in severe psychiatric disorders and brain morphology. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 449-450.	1.8	1
190	Risk genes, metabolic syndrome and eye tracking deficits in psychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 177-179.	1.8	1
191	Schizophrenia: brain morphology and treatment aspects. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 1-2.	1.8	1
192	Family load impacts orbitofrontal volume in first-episode schizophrenia. Psychiatry Research - Neuroimaging, 2015, 232, 130-133.	0.9	1
193	Pathways to personalized treatment strategies for depressive disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 1-3.	1.8	1
194	Genetic and environmental risk factors in neurodevelopmental disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 445-447.	1.8	1
195	Stepping up: the just released new impact factor 2015. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 475-476.	1.8	1
196	Impaired recovery in affective disorders and schizophrenia: sharing a common pathophysiology?. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 739-740.	1.8	1
197	Failed regeneration and inflammation in schizophrenia: two sides of the same coin?. Journal of Neural Transmission, 2022, , 1.	1.4	1
198	The Hypoxic Rat Model for Obstetric Complications in Schizophrenia. Neuromethods, 2011, , 93-111.	0.2	0

#	Article	IF	CITATIONS
199	On our own behalf: a new editorial board and focus of EAPCN. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 545-546.	1.8	0
200	Post-mortem findings in mood disorders, nightmares and therapeutic approaches of psychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 635-636.	1.8	0
201	Selected issues of the DGPPN Congress in 2011. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 49-50.	1.8	0
202	The glutamate system as a therapeutic target and impact of genes on suicidality. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 365-366.	1.8	0
203	Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 271-272.	1.8	Ο
204	Selected topics of the DGPPN Congress 2012. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 121-122.	1.8	0
205	Brain imaging to be on track for improving diagnosis and pathophysiological insights in neuropsychiatric diseases. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 537-538.	1.8	Ο
206	Selected issues of the DGPPN Congress in 2013. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 1-2.	1.8	0
207	Proteomic Characterization of the Brain and Cerebrospinal Fluid of Schizophrenia Patients. Advances in Biological Psychiatry, 2014, , 1-1.	0.2	0
208	New aspects of cognition domains and psychopathological measures in psychiatry. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 647-649.	1.8	0
209	Connectivity and cognition in neuropsychiatric disorders with special emphasis on Alzheimer's disease and Chorea Huntington. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 465-466.	1.8	0
210	Reward, memory and prediction of treatment response in affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 185-186.	1.8	0
211	Unravelling basic mechanisms in addiction and neuropsychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 633-635.	1.8	Ο
212	DGPPN guideline on anxiety disorders and cognitive dysfunction in the elderly or patients with multiple sclerosis. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 361-362.	1.8	0
213	Aerobic exercise for people with schizophrenic psychosis. , 2016, , 66-78.		Ο
214	Neurobiological background of borderline personality disorder, PTSD and ADHD. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 289-290.	1.8	0
215	On the search of new treatment strategies in patients with affective disorders. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 709-710.	1.8	0
216	11.3 CLINICAL AND NEUROBIOLOGICAL EFFECTS OF A CONTINUOUS AEROBIC ENDURANCE TRAINING IN MULTI-EPISODE SCHIZOPHRENIA PATIENTS. Schizophrenia Bulletin, 2018, 44, S17-S18.	2.3	0

#	Article	IF	CITATIONS
217	Modeling Obstetric Complications in Schizophrenia. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2020, 5, 1070-1071.	1.1	ο
218	Affected neural networks as basis of disturbed motor function in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 279-280.	1.8	0
219	Verbesserung der GehirnplastizitĤbei der Schizophrenie: Möglichkeit therapeutischer Verbesserungen?. , 2019, , 83-96.		0
220	Brain changes in psychosis. , 2019, , 45-56.		0
221	Improving brain plasticity in schizophrenia: possibility for therapeutic advancements?. , 2019, , 85-96.		Ο
222	The efficacy and safety of cariprazine in the early and late stage of schizophrenia: a post hoc analysis of three randomized, placebo-controlled trials. CNS Spectrums, 2021, , 1-8.	0.7	0